Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

Colon Neoadjuvant FOLFOXIRI Study

Phase 2

Active, not recruiting

Conditions: Rectal Cancer

Interventions: Drug: neoadjuvant FOLFOXIRI
Drug: Capecitabine

First Posted Date: 2013-09-13

Last Posted Date: 2024-06-24

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 40

Registration Number: NCT01941641

Locations: 🇭🇰
Department of Clinical Oncology, Hong Kong, Hong Kong

Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Nimotuzumab
Drug: docetaxel
Drug: capecitabine

First Posted Date: 2013-09-11

Last Posted Date: 2015-06-04

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 90

Registration Number: NCT01939054

Locations: 🇨🇳
Xijing Hospital, Xi-an, Shanxi, China
🇨🇳
The General Hospital of the People's Liberation Army (PLAGH), Beijing, Beijing, China
🇨🇳
Beijing cancer hospital, Beijing, Beijing, China

and more 6 locations

Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Capecitabine
Drug: aromatase Inhibitors (AIs)

First Posted Date: 2013-08-16

Last Posted Date: 2013-08-16

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT01924078

Locations: 🇨🇳
FUSCC, Shanghai, Shanghai, China

High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Phase 2

Terminated

Conditions: Pancreatic Adenocarcinoma
Stage III Pancreatic Cancer

Interventions: Radiation: low intensity radiation therapy
Drug: Capecitabine
Drug: nab-Paclitaxel
Drug: Gemcitabine
Radiation: high intensity radiation therapy

First Posted Date: 2013-08-13

Last Posted Date: 2018-07-13

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 20

Registration Number: NCT01921751

Locations: 🇺🇸
Radiation Oncology Associates PC, Fort Wayne, Indiana, United States
🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

and more 43 locations

S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.

Phase 3

Completed

Conditions: Colorectal Cancer
Metastases

Interventions: Drug: Capecitabine
Drug: Teysuno
Drug: Bevacizumab

First Posted Date: 2013-08-08

Last Posted Date: 2018-03-14

Lead Sponsor: Dutch Colorectal Cancer Group

Target Recruit Count: 161

Registration Number: NCT01918852

Locations: 🇳🇱
Slingeland Ziekenhuis, Doetinchem, Netherlands
🇳🇱
Orbis Medisch Centrum, Sittard, Netherlands
🇳🇱
Tweesteden Ziekenhuis, Tilburg, Netherlands

and more 21 locations

Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer

Phase 1

Completed

Conditions: Stage IB Pancreatic Cancer
Stage IA Pancreatic Cancer
Stage IIA Pancreatic Cancer
Stage IIB Pancreatic Cancer

Interventions: Radiation: stereotactic body radiation therapy
Drug: capecitabine
Procedure: therapeutic conventional surgery
Procedure: magnetic resonance imaging
Other: laboratory biomarker analysis